B Active

Not all B vitamins are created equal. The biochemical form of each vitamin in your B complex determines its action in the body.
That’s why we love B Active, which is carefully formulated with the highest potency forms in a balanced blend for optimal metabolic response:

• B Active contains the activated forms of B2 and B6, and the methylated forms of B9 and B12 to ensure full biological activity.
• Folate (B9) is provided as Quatrefolic®, a patented glucosamine salt of methylated folate that has been proven to have greater stability, solubility, and bioavailability than other forms of methylfolate.1

A potent dose of thiamin (B1) is provided alongside benfotiamine, a potent and bioavailable fat-soluble form of vitamin B1 derived from garlic, with unique antioxidant and immunomodulatory benefits.2

1 CAPSULE PER SERVING

Thiamin (as thiamine HCl) 20 mg

Riboflavin (as riboflavin 5’-phosphate sodium) 20 mg

Niacin (as niacinamide and niacin) 140 mg

Vitamin B6 (as pyridoxal 5’-phosphate) 20 mg

Folate (as (6S)-5-methyltetrahydrofolic acid, glucosamine salt) 400 mcg DFE

Vitamin B12 (as methylcobalamin) 400 mcg

Biotin 400 mcg

Pantothenic Acid (as d-calcium pantothenate) 150 mg

Choline (as choline dihydrogen citrate) 30 mg

Benfotiamine 20 mg

​​Other Ingredients: Capsule (hypromellose and water), stearic acid, magnesium stearate, and silica

FORMULATED TO EXCLUDE: Wheat, gluten, corn, yeast, soy, animal and dairy
products, fish, shellfish, peanuts, tree nuts, egg, GMOs, artificial colors, artificial sweeteners, and artificial preservatives.

Take one capsule once or twice daily, or as directed by your healthcare professional.

Caution: Individuals taking medication should discuss potential interactions with their healthcare professional.

Therapeutic potential of vitamin B1 derivative benfotiamine from diabetes to COVID-19

Benfotiamine (S-benzoylthiamine-O-monophosphate), a unique, lipid-soluble derivative of thiamine, is the most potent allithiamine found in roasted garlic, as well as in other herbs of the genusAllium. In addition to potent antioxidative properties, benfotiamine has also been shown to be a strong anti-inflammatory agent with therapeutic significance to several pathological complications. Specifically, over the past decade or so, benfotiamine has been shown to prevent not only various secondary diabetic complications but also several inflammatory complications such as uveitis and endotoxemia. Recent studies also demonstrate that this compound could be used to prevent the symptoms associated with various infectious diseases such as HIV and COVID-19. In this review article, the authors discuss the significance of benfotiamine in the prevention of various pathological complications.

Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats

Background: Folates play an important role to prevent neurological disorders in embryo development and in cardiovascular diseases. Folate supplementation is suggested, particularly in females of childbearing age, for the prevention of embryonal NTDs during pregnancy. Folic acid and reduced folate ((6S)5-MTHF) are currently used in supplementation. The aim of this study was to compare the bioavailability of Quatrefolic®, a novel patented (6S)5-MTHF glucosamine salt, with (6S)5-MTHF calcium salt and folic acid in Sprague Dawley rats.

Methods: Fifty-four to fifty-five-day old male Sprague-Dawley rats were divided in 3 treatment groups, each comprising 6 animals, receiving folic acid, (6S)5-MTHF calcium salt or Quatrefolic® at the dose of 70 µg/kg of (6S)5-MTHF equivalents in a single oral administration. Folates were determined in plasma with a HPLC method employing fluorimetric detection. (6S)5-MTHF level was chosen as a convenient end point to evaluate folate absorption. The main pharmacokinetic parameters were calculated (Cmax, tmax, AUC).

Results: Quatrefolic® administration produced a plasmatic (6S)5-MTHF concentration peak (Cmax: 879.6±330.3 ng/mL) 1.8 times higher than (6S)5-MTHF Ca salt (486.8±184.1 ng/mL), and 3.1 times higher than folic acid supplementation (281.5±135.7 ng/mL), while tmax values were similar for the three folate forms. Quatrefolic® supplementation showed AUC8h (1123.9 ng/mL ∙ h) 9.7 times higher than folic acid (114.7 ng/mL ∙ h) and 1.12 times higher than (6S)5-MTHF Ca salt (997.6 ng/mL ∙ h).

Conclusions: Quatrefolic® has demonstrated an enhanced oral bioavailability in comparison to other reduced folates and to folic acid in rats.